List of Excipients in Branded Drug DEFLAZACORT

Generic Drugs Containing DEFLAZACORT

Company	Ingredient	NDC	Excipient
Upsher-Smith Laboratories LLC	deflazacort	0832-0815	LACTOSE MONOHYDRATE
Upsher-Smith Laboratories LLC	deflazacort	0832-0815	MAGNESIUM STEARATE
Upsher-Smith Laboratories LLC	deflazacort	0832-0815	SILICON DIOXIDE
Upsher-Smith Laboratories LLC	deflazacort	0832-0815	STARCH, CORN
Aurobindo Pharma Limited	deflazacort	59651-599	LACTOSE MONOHYDRATE
Aurobindo Pharma Limited	deflazacort	59651-599	MAGNESIUM STEARATE
Aurobindo Pharma Limited	deflazacort	59651-599	POLYSORBATE 80

What are the Most Frequently-Used Excipients in DEFLAZACORT?

# Of NDCs	Excipient
7	LACTOSE MONOHYDRATE
7	MAGNESIUM STEARATE
1	POLYSORBATE 80
7	SILICON DIOXIDE
7	STARCH, CORN

Deflazacort Excipient Strategy and Commercial Opportunities

Last updated: August 21, 2026

Deflazacort has a strong excipient-driven product opportunity because the active ingredient is used primarily in pediatric Duchenne muscular dystrophy (DMD), where dose flexibility, palatability, swallowability, dosing accuracy, and chronic-use tolerability affect product selection. The largest opportunities are ready-to-use oral liquids, lower-volume concentrated suspensions, orally disintegrating tablets, sprinkle products, and formulations that reduce sugar, alcohol, allergen, or gastrointestinal excipient exposure.

Emflaza, the U.S. reference product, is approved as 6 mg, 18 mg, 30 mg, and 36 mg tablets and as a 22.75 mg/mL oral suspension for patients at least 2 years old with DMD.[1] The FDA-approved suspension uses a conventional excipient system containing citric acid, edetate disodium, hypromellose, polysorbate 80, sodium citrate, sorbitol, and water.[1] This composition establishes a practical benchmark for generic, specialty, and lifecycle-management products.

What is deflazacort and why do excipients matter?

Deflazacort is an oxazoline derivative corticosteroid and prodrug of 21-desacetyldeflazacort. It is administered chronically in DMD, where patients may have limited swallowing ability, variable caregiver support, and high sensitivity to taste and dosing errors.

The formulation challenges are commercially important:

Formulation issue	Commercial consequence
Poor aqueous solubility of the active ingredient	Requires suspension engineering, particle-size control, or solubilization support
Pediatric chronic use	Drives demand for palatable, low-burden dosage forms
Weight-based dosing	Requires accurate measuring devices and dose flexibility
Multiple tablet strengths	Creates inventory and adherence complexity
Long-term corticosteroid therapy	Increases attention to sugar, alcohol, sodium, allergen, and gastrointestinal excipients
DMD-associated weakness	Favors liquids, dispersible tablets, and easy-open packaging
Caregiver administration	Makes sedimentation, redispersibility, and dose reproducibility critical

The commercial value of excipients is therefore tied to performance, not simply ingredient cost. A formulation that improves dosing accuracy or reduces administration burden can compete even when the active pharmaceutical ingredient is generic.

What excipients are used in the FDA-approved Emflaza suspension?

The Emflaza oral suspension contains the following inactive ingredients:

Excipient	Functional role
Hypromellose	Suspending and viscosity-modifying agent
Polysorbate 80	Wetting and dispersing agent
Sorbitol	Sweetener and bulking agent
Citric acid and sodium citrate	Buffer system and pH control
Edetate disodium	Chelating agent and stability support
Purified water	Vehicle

The product concentration is 22.75 mg/mL deflazacort. The label instructs users to shake the suspension before administration and to measure doses with an oral syringe.[1] The formulation strategy relies on a structured suspension rather than a true aqueous solution. That distinction creates potential differentiation opportunities in particle engineering, rheology, device integration, and reconstitution or redispersion performance.

What does each excipient contribute?

Hypromellose increases continuous-phase viscosity and slows sedimentation. Its grade, substitution pattern, concentration, and hydration behavior influence pourability and syringeability. Excessive viscosity can improve physical stability but increase dosing resistance and leave residue in the bottle or syringe.

Polysorbate 80 improves wetting of hydrophobic drug particles and supports dispersion. Its concentration must be balanced against oxidation, peroxide impurities, potential degradation pathways, and taste impact.

Sorbitol provides sweetness and body. It is commercially useful in pediatric formulations but can produce gastrointestinal effects at higher exposures. A sugar-free product may still use polyols, so labeling and tolerability claims require careful review.

The citrate buffer controls pH and contributes to taste. Buffer selection affects chemical stability, preservative strategy, particle surface behavior, and compatibility with packaging.

Edetate disodium binds trace metals that can catalyze degradation. It may improve stability but adds another excipient declaration and can complicate product positioning for consumers seeking minimal-ingredient formulations.

Which deflazacort excipient strategies offer the strongest commercial opportunities?

The most attractive opportunities are pediatric liquid optimization, differentiated suspension technology, and alternative solid oral dosage forms.

1. Low-volume concentrated suspension

A concentrated suspension could reduce the volume administered at higher doses. The reference product delivers 30 mg in approximately 1.32 mL at its labeled concentration. A higher-strength product could reduce caregiver burden if it maintains dose uniformity, acceptable viscosity, and a safe dosing device.

The main development risks are:

• Increased sedimentation or caking at higher drug loading
• Greater dose error from small measurement volumes
• More pronounced taste and mouthfeel
• Higher viscosity and poor syringe flow
• Greater sensitivity to particle-size distribution
• Need for new stability and in-use data

A concentrated product may be commercially valuable for older or heavier patients who require larger daily doses. The opportunity is strongest if the formulation can use a low-dead-space oral syringe with a dose-marking system that reduces caregiver calculation.

2. Improved-palatability suspension

Taste remains a significant barrier in chronic pediatric corticosteroid therapy. Deflazacort has an active or formulation-related bitterness that may require masking.

Potential approaches include:

• High-intensity sweeteners such as sucralose or acesulfame potassium
• Flavor systems selected through pediatric sensory testing
• Ion-exchange resin complexes
• Lipid or polymer coating of drug particles
• Microencapsulation
• Cyclodextrin-based complexation
• Taste-masking polymers
• Multiparticulate delivery systems

Taste masking must not materially delay redispersion, reduce dose recovery, or alter dissolution after administration. A formulation with strong taste performance could compete through adherence and caregiver preference, even if it has no therapeutic difference.

3. Sugar-reduced or polyol-optimized liquid

The reference suspension uses sorbitol. A competing product could target families and prescribers seeking reduced sugar or lower gastrointestinal burden.

Possible strategies include:

• Lower sorbitol concentration
• Sucralose-based sweetness
• Acesulfame potassium or steviol glycosides
• Combination sweetener systems
• Reduced total solids
• Sugar-free labeling supported by the complete excipient profile

Steviol glycosides may introduce bitterness and aftertaste. High-intensity sweeteners can require flavor correction. Polyol reduction can also affect viscosity, mouthfeel, and suspension stability. The best commercial design would optimize palatability without simply replacing sorbitol with a more difficult excipient system.

4. Alcohol-free and preservative-free suspension

An alcohol-free product can support pediatric positioning and international market access. The reference formulation does not list ethanol as an inactive ingredient.[1] A preservative-free multidose presentation would be more difficult because microbial control must come from packaging, water activity, manufacturing controls, or single-dose units.

Commercial formats could include:

• Unit-dose oral suspension cups
• Blow-fill-seal ampoules
• Metered multidose bottles
• Barrier bottles with integrated adapters
• Sachets containing dry powder for reconstitution

Single-dose packaging increases manufacturing and packaging cost but can improve portability and reduce in-use contamination risk.

5. Orally disintegrating or dispersible tablets

Deflazacort tablets are already available in multiple strengths. A dispersible or orally disintegrating tablet could address patients who cannot swallow conventional tablets but do not need a liquid.

Excipients may include:

• Mannitol for cooling sensation and mouthfeel
• Crospovidone or croscarmellose sodium for rapid disintegration
• Microcrystalline cellulose for structure
• Low-substituted hydroxypropyl cellulose
• Sucralose and flavor systems
• Magnesium stearate at controlled levels
• Co-processed direct-compression excipients

The principal development issue is dose uniformity at low strengths. A 6 mg product may require robust content uniformity controls, especially where the active is poorly soluble and the tablet contains a relatively small drug load.

6. Sprinkle capsules or multiparticulates

Sprinkle formulations can be administered over soft food or through selected enteral feeding systems, subject to product-specific compatibility. They may be useful for patients with swallowing impairment.

Multiparticulates could combine:

• Taste-masked drug-loaded pellets
• Immediate-release polymer coatings
• Controlled particle-size populations
• Dose-flexible sachets or capsules
• Food-compatible administration instructions

The regulatory burden is higher than for a conventional tablet because the sponsor must characterize particle coating, release after administration with food, dose recovery, and device or tube compatibility where claimed.

What formulation patents could protect a differentiated deflazacort product?

The active ingredient itself has limited lifecycle value compared with formulation and delivery claims. Potentially protectable subject matter includes:

Patent area	Example claim focus
Suspension composition	Deflazacort, polymeric suspending agent, surfactant, buffer, sweetener, and defined pH range
Particle engineering	Micronized or engineered particles with specified D90, morphology, or surface treatment
Taste masking	Coated particles, resin complexes, polymer matrices, or encapsulated drug
Stability	Reduced degradation over a defined shelf life or in-use period
Concentrated dosage form	Higher drug concentration with specified viscosity and dose uniformity
Device integration	Bottle adapter, oral syringe, dosing cap, or metered delivery system
Dispersible tablet	Rapid disintegration, dose uniformity, and dissolution performance
Sprinkle product	Multiparticulate dosage form with food or enteral administration
Manufacturing process	Wet milling, spray drying, granulation, coating, or controlled drying
Packaging	Moisture- or oxygen-barrier container supporting stability

Patent strength is generally higher where claims connect composition to a measurable performance result. Broad claims covering a deflazacort suspension with ordinary excipients may face validity and obviousness challenges. Narrow claims based on particle size, viscosity, redispersibility, dissolution, stability, or taste-mask performance may be more defensible if supported by comparative data.

A sponsor should avoid relying exclusively on excipient identity. The stronger strategy is a layered estate covering:

1. Composition.
2. Drug-particle attributes.
3. Manufacturing process.
4. Packaging and device.
5. Stability and in-use performance.
6. Pediatric administration method.

What is the Orange Book and FDA regulatory status of deflazacort?

The FDA approved Emflaza in February 2017 for the treatment of DMD in patients 2 years of age and older.[2] The product received orphan-drug designation and approval for a rare pediatric neuromuscular disease.

The U.S. reference products include tablets and oral suspension. Orange Book-listed patents and exclusivity should be reviewed by dosage form and product-specific listing because formulation, method-of-use, and drug-product patents may have different expiration dates and relevance to an ANDA applicant.[3]

The seven-year orphan-drug exclusivity period associated with the 2017 approval generally reached its statutory end in February 2024, subject to the scope of the approved indication and applicable regulatory events.[2] Orphan exclusivity does not prevent all generic activity outside the protected indication, and it does not replace patent analysis.

What Paragraph IV risks exist for deflazacort?

An ANDA applicant can challenge listed patents through a Paragraph IV certification. The commercial exposure depends on:

• Whether the listed patent covers tablets, suspension, or both
• Whether the applicant seeks all strengths or selected strengths
• Whether a method-of-use patent remains relevant
• Whether the applicant launches at risk
• Whether the reference sponsor files infringement litigation within the statutory period
• Whether litigation triggers a 30-month stay
• Whether the challenged patent is later narrowed, invalidated, or expires

A generic suspension faces more formulation-specific risk than a simple tablet if the reference sponsor has enforceable claims covering particle engineering, suspension performance, or a specific excipient combination. A tablet applicant may pursue a non-infringing formulation with a different disintegrant, filler, lubricant, or coating system.

When does deflazacort lose exclusivity?

Regulatory and patent exclusivity are separate.

Exclusivity layer	Relevance to deflazacort
New chemical entity exclusivity	Not the principal U.S. protection associated with Emflaza because deflazacort was previously approved outside the United States
Orphan-drug exclusivity	Associated with the DMD approval and generally ran for seven years from the 2017 approval
Pediatric exclusivity	Could extend applicable marketing exclusivity if separately granted
Listed patents	May protect drug product, formulation, method of use, or other approved-product attributes
Data exclusivity	Depends on the regulatory pathway and reference-product history
Trade secrets	Can protect manufacturing parameters, flavor systems, and process controls without appearing in the Orange Book

The practical generic-entry date is determined by the latest enforceable barrier that applies to the proposed product and indication. A generic applicant can enter earlier through a successful Paragraph IV challenge, a licensed launch, or a non-infringing product strategy.

Which companies are positioned in the deflazacort market?

PTC Therapeutics commercialized Emflaza in the United States after acquiring the product and related assets from Marathon Pharmaceuticals.[4] The commercial market includes:

• The reference product marketed by PTC Therapeutics
• ANDA applicants developing generic tablets or oral suspension
• Specialty-pharmacy distributors
• Contract manufacturers with pediatric liquid capabilities
• Excipients and formulation technology suppliers
• Potential regional licensees in markets where deflazacort has an established corticosteroid history

The most credible competitors are not limited to traditional generic tablet manufacturers. Companies with suspension manufacturing, pediatric flavor development, oral syringe packaging, and regulatory experience in rare diseases may have a stronger commercial position.

How does deflazacort compare with prednisone and prednisolone?

Deflazacort competes clinically and commercially with prednisone and prednisolone, both of which are available in multiple generic formulations. Deflazacort is often positioned around DMD-specific clinical use, chronic corticosteroid management, and potentially different weight-gain or bone-health considerations, although product selection remains physician-specific and evidence must be interpreted within the relevant treatment context.

Attribute	Deflazacort	Prednisone	Prednisolone
DMD commercial positioning	Strong U.S. orphan-drug positioning	Broad generic use	Broad generic use
Pediatric liquid availability	Reference suspension available	Widely available	Widely available
Generic price pressure	Increasing after exclusivity loss	High	High
Differentiation opportunity	Suspension, taste, device, dose flexibility	Limited for standard products	Flavor and dosage-form differentiation
Patent opportunity	Formulation and delivery claims	Usually limited for mature products	Usually limited for mature products
Caregiver value drivers	Dosing accuracy and tolerability	Cost and availability	Taste, concentration, and availability

Deflazacort’s commercial advantage is less likely to come from an ordinary tablet. It is more likely to come from a superior pediatric delivery system that reduces administration friction relative to inexpensive prednisone or prednisolone liquids.

What manufacturing and intellectual-property barriers matter most?

The main technical barrier is reproducible suspension performance. A sponsor must control:

• Active particle-size distribution
• Wetting and deagglomeration
• Sedimentation rate
• Caking tendency
• Redispersibility after storage
• Dose uniformity throughout bottle use
• Viscosity at different temperatures
• Syringeability
• Microbial quality
• Container-closure compatibility
• Chemical and physical stability

Suspensions may pass initial release testing yet fail during in-use studies. The first and last doses in a bottle must remain representative. Bottle geometry, headspace, shaking instructions, adapter design, and syringe selection can materially affect delivered dose.

Manufacturing know-how may include milling energy, order of excipient addition, hydration time for hypromellose, surfactant premixing, deaeration, filling temperature, and hold-time controls. These parameters can form valuable trade secrets even when they are not patent-protected.

What licensing deals could create commercial value?

Potential licensing targets include:

• Regional rights to deflazacort tablets or suspension
• Pediatric liquid technology
• Taste-masking platforms
• Spray-dried or coated-particle manufacturing
• Oral syringe and bottle-adapter systems
• Specialty-pharmacy distribution rights
• Co-development agreements with DMD-focused companies

A licensee should value the product on net sales after generic erosion, not on historical reference-product revenue alone. A differentiated formulation can justify a higher valuation when it has a separate regulatory pathway, non-infringing composition, device protection, and evidence of caregiver preference.

The strongest transaction structure would link milestone payments to FDA approval, patent clearance, commercial launch, and sales thresholds. Territory-specific rights may be preferable because deflazacort regulatory status, reimbursement, and pediatric liquid competition vary materially by jurisdiction.

What generic launch scenarios exist for deflazacort?

Early launch after successful patent challenge

An ANDA applicant may launch before all listed patents expire if it prevails in Paragraph IV litigation or reaches a settlement permitting an agreed entry date. This scenario creates the highest downside for the reference product but carries litigation and supply-chain risk for the generic company.

Authorized or licensed generic entry

A settlement or license can establish a controlled entry date. The reference sponsor may preserve part of the market through an authorized generic or a co-marketed product.

Tablet-first generic entry

A company may launch tablets before suspension, targeting older patients and lower manufacturing complexity. This approach can capture price-sensitive prescriptions but leaves pediatric liquid demand exposed to the reference product.

Suspension-led differentiated entry

A generic suspension with improved taste, packaging, or dose flexibility may gain share despite limited price separation. The product must demonstrate pharmaceutical equivalence and meet applicable inactive-ingredient requirements.

Niche lifecycle product

A sponsor can avoid direct tablet competition with an orally disintegrating, sprinkle, unit-dose, or concentrated suspension product. The regulatory and patent pathway is more complex, but the product may support better net pricing.

What is the revenue exposure from deflazacort competition?

The largest exposure is concentrated in the U.S. DMD market because Emflaza received orphan-drug positioning and has been sold through specialty channels. Revenue risk increases when:

• Orphan exclusivity ends
• Multiple ANDAs receive approval
• Generic suspension becomes available
• Payers impose mandatory generic substitution
• Patients transition from liquid to lower-cost tablets
• Competing corticosteroids are used off-label
• Specialty-pharmacy access advantages diminish

Reference-product revenue can remain resilient if the brand has clinical familiarity, patient-support services, reimbursement access, or a formulation advantage. Those protections weaken when a generic matches the same strength, concentration, excipient profile, and delivery device.

How strong is the deflazacort patent estate?

The strongest potential protection is likely to be product-specific formulation, method-of-use, process, and device protection rather than broad active-ingredient protection.

Estate component	Relative strategic value
Broad active-ingredient claims	Low for a mature, previously known corticosteroid
Tablet composition claims	Moderate if tied to non-obvious performance
Oral suspension claims	Moderate to high if supported by narrow excipient and performance limitations
Taste-masking claims	Moderate, dependent on technical data
Manufacturing claims	Moderate, with trade-secret overlap
Device and packaging claims	Moderate, especially for dose accuracy
Method-of-use claims	Relevant where tied to the approved DMD indication
Pediatric dosing claims	Potentially valuable but vulnerable to obviousness and written-description attacks

Patent strength depends on claim scope, priority dates, prosecution history, Orange Book listing, and the availability of non-infringing alternatives. A formulation patent that can be designed around by changing the suspending polymer or sweetener may have limited exclusionary value unless the claims cover the critical performance range.

Key Takeaways

• Deflazacort’s highest-value commercial opportunity is pediatric delivery, not an undifferentiated tablet.
• The Emflaza suspension uses hypromellose, polysorbate 80, sorbitol, citrate buffer, edetate disodium, and water.
• Concentrated suspensions, improved taste, low-volume dosing, dispersible tablets, and sprinkle products are the leading lifecycle strategies.
• Suspension performance depends on particle size, wetting, viscosity, redispersibility, dose uniformity, and device compatibility.
• Formulation patents are more commercially relevant than broad active-ingredient patents.
• Orphan-drug exclusivity associated with the 2017 U.S. approval generally ended in February 2024, while patent and regulatory barriers require separate analysis.
• Generic risk is highest when an ANDA matches both the reference tablet and suspension markets.
• A differentiated liquid can preserve pricing only if it delivers measurable benefits in palatability, dosing accuracy, stability, packaging, or administration.
• Licensing value depends on remaining exclusivity, regulatory pathway, formulation differentiation, manufacturing capability, and specialty-pharmacy access.

FAQs

Can deflazacort be formulated as a true oral solution?

A true solution may be technically challenging because deflazacort has limited aqueous solubility. Cosolvents, surfactants, complexing agents, or pH adjustment could improve apparent solubility, but each approach creates pediatric tolerability, taste, stability, and regulatory constraints.

Which excipient is most important for deflazacort suspension stability?

No single excipient controls performance. Hypromellose provides suspension structure, while polysorbate 80 supports wetting. Particle-size control and processing conditions are equally important and may determine whether the system redisperses consistently.

Is a sugar-free deflazacort suspension commercially attractive?

Yes. A sugar-free or reduced-polyol product could appeal to caregivers and prescribers seeking a cleaner pediatric formulation. The commercial benefit depends on taste, gastrointestinal tolerability, stability, and whether the product maintains acceptable suspension performance.

Can an excipient change create a separate deflazacort patent?

It can, but a mere substitution of one conventional excipient for another is unlikely to provide strong protection without unexpected results. The strongest claims connect the excipient system to measurable improvements such as stability, dose uniformity, taste masking, or redispersibility.

Is there biosimilar risk for deflazacort?

No. Deflazacort is a small-molecule corticosteroid, so the relevant competitive threat is generic substitution through the ANDA pathway, not biosimilar approval under the Public Health Service Act.

References

1. PTC Therapeutics, Inc. (2024). Emflaza (deflazacort) tablets and oral suspension: Prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2017). FDA approves Emflaza for Duchenne muscular dystrophy. https://www.fda.gov

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. PTC Therapeutics, Inc. (2017). PTC Therapeutics completes acquisition of Emflaza from Marathon Pharmaceuticals. Company press release.